Beovu Initial Experience

Beovu is out and finally we have some very preliminary patient results to share. I recently wrote about why Beovu would potentially be superior to what we have available – ARTICLE.

There is a higher molar dose of anti-VEGF delivered with Beovu and a smaller molecular size which might have better retinal penetration. Lastly in the study, there was an observed better drying effect over Eylea (aflibercept) in the first few months of the study.

Trying to determine which patients are right for the drug was my first question. I’ve had patients with success on agents now some of which I’ve extended to 10 or 12 weeks. However, I do have many patients that I cannot extend beyond 4-8 weeks for which I thought this drug would be perfect for.

Here are a couple of case examples. Please note this is a noncomparative series and individual cases so to make sweeping conclusions is not possible.

Overall, I am quite impressed with the amount of fluid reduction I am seeing which I would rate at or better than what I observed with Eylea (aflibercept). There are no signs of adverse events thus far on the handful of patients I have treated. Looking forward to seeing more patients return to better assess the response.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close